Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
64.6M
-
Shares change
-
+1.6M
-
Total reported value, excl. options
-
$1.76B
-
Value change
-
+$43.6M
-
Put/Call ratio
-
0.21
-
Number of buys
-
43
-
Number of sells
-
-35
-
Price
-
$27.26
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q3 2019
108 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q3 2019.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.6M shares
of 226M outstanding shares and own 28.55% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (21.2M shares), FMR LLC (5.53M shares), Capital Research Global Investors (5.27M shares), BlackRock Inc. (4M shares), VANGUARD GROUP INC (3.95M shares), Capital International Investors (3.94M shares), Capital World Investors (3.28M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.52M shares), ALLIANCEBERNSTEIN L.P. (1.61M shares), and PERCEPTIVE ADVISORS LLC (1.54M shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.